Navigation Links
Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
Date:8/29/2010

s is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Additional InformationThis communication does not constitute an offer to buy or solicitation of an offer to sell any securities.  No tender offer for the shares of Genzyme Corporation ("Genzyme") has commenced at this time.  In connection with the proposed transaction Sanofi-aventis ("Sanofi-aventis") may file tender offer documents with the U.S. Securities and Exchange Commission ("SEC").  Any definitive tender offer documents will be mailed to shareholders of Genzyme.  INVESTORS AND SECURITY HOLDERS OF GENZYME ARE URGED TO READ THESE AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.  Investors and security holders will be able to obtain free copies of these documents (if and when available) and other documents filed with the SEC by Sanofi-aventis through the web site maintained by the SEC at http://www.sec.gov.

Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends,""estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and st
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries
2. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
3. Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc.
4. Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
5. Sanofi-aventis Obtains Antitrust Clearance in Connection With Chattem, Inc. Tender Offer
6. Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc.
7. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
8. Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector
9. Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America
10. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
11. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... /PRNewswire-iReach/ -- Reproductive Medicine Associates of New York ... a nationally and internationally-recognized leader in providing exceptional quality ... pleased to announce a new collaboration with EMD Serono ... recognize the sacrifices made by veterans and their families ... will allow qualifying veterans and the spouses of veterans ...
(Date:7/22/2014)... , July 22, 2014 BioDelivery Sciences ... that its Board of Directors has appointed Charles ... Feinberg as members of the Board.  ... with extensive experience in marketing, sales and other commercial ... Pearl Therapeutics, Inc., a development stage company that was ...
(Date:7/22/2014)... , July 22, 2014  NeuroSigma, Inc. (NeuroSigma), a ... on commercialization of its non-invasive Monarch ™ ... neuropsychiatric disorders, today announced that enrollment has begun in ... stimulation (eTNS) as adjunctive therapy for the treatment of ... conducted at the Olive View-UCLA Medical Center in ...
Breaking Medicine Technology:Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 2Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 3BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 2BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 3BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 4BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 6BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 7Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5
(Date:7/22/2014)... Va. (PRWEB) July 22, 2014 ... 10, at the Ronald Reagan Building and International ... Forward: Warriors, Military Families and Civilian Communities,” will ... (registration opens at 7:30 a.m.) and cohosted by ... the National Defense Industrial Association (NDIA). USAA is ...
(Date:7/22/2014)... Aaron Marshall, Corporate Counsel at Northrop Grumman, will ... Agency for the 2014-2015 fiscal year. He joined the ... states, "“Serving on the HASA board has given me a ... me remember how much others need help." , ABOUT AARON ... has a B.S. in Finance from the University of Delaware. ...
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July 22, 2014 ... deep in the veins of the legs appear no different ... greater risk of bleeding and average hospitalization bills that are ... study finds. The standard treatment for these clots -- ... and compression stockings. The other, more expensive treatment delivers medication ...
(Date:7/22/2014)... The American Society of Hematology (ASH) will honor Tomas ... Los Angeles with the 2014 E. Donnall Thomas Lecture ... discovery of the iron-regulatory hormone hepcidin and investigation of ... the Nobel Prize Laureate and past Society president E. ... that have represented a paradigm shift or significant discovery ...
(Date:7/22/2014)... electric power morcellation, uterine cancers were present in 27 ... according to a study published by JAMA . ... the uterus is fragmented into smaller pieces, may result ... commercial availability of electric power morcellators for 2 decades, ... time of electric power morcellation (in this study referred ...
Breaking Medicine News(10 mins):Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:New Board President for Baltimore-based Nonprofit 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2
... cancer may also mean surviving pain, according to a study ... of cancer survivors at least two years post diagnosis have ... ahead of print in the American Cancer Society,s journal ... among the growing number of U.S. cancer survivors. ...
... Jan. 13 (HealthDay News) -- This winter will not be a ... to be a more typical flu season, experts say. And ... shot, advice that seniors in particular should heed since the prevalent ... hardest, the experts added. The H1N1 flu virus tended to strike ...
... data from counties across the United States led to the ... risk factor for suicide, according to a provocative study published ... Biology , a peer-reviewed journal published by Mary Ann Liebert, ... Brenner, MD, PhD, and David Cheng, MD, University Hospitals Case ...
... receive more information about the pitfalls of breast cancer screening, ... false-positive results faced serious anxiety and reduced quality of life ... online by BJS, the British Journal of Surgery , ... is abnormal but no cancer is present - had to ...
... COLUMBUS, Ohio New research shows that oncolytic viruses, ... more effective in treating deadly brain tumors if equipped ... The enzyme, called chondroitinase, helps the cancer-killing virus clear ... fill space between cells and impede the virus,s movement ...
... the Kimmel Cancer Center at Jefferson and two other ... protein SIRT1, known for its life-spanning effects in different ... to prostate cancer, prostatic intraepithelial neoplasia (PIN). ... cancer prevention drugs that could not only block prostate ...
Cached Medicine News:Health News:Cancer survivors likely to experience pain at some point in care: U-M study shows 2Health News:Flu Season Looks Normal This Year, Experts Say 2Health News:Women with false-positive mammograms report high anxiety and reduced quality of life 2Health News:Women with false-positive mammograms report high anxiety and reduced quality of life 3Health News:Virus might fight brain tumors better if armed with bacterial enzyme, study shows 2Health News:'Longevity' protein SIRT1 may ward off precursor to prostate cancer 2
... the typical patient, right for the not-so-typical ... you have the ability to address the ... least expect themeven after implant. St. Jude ... to be prepared in almost any situation, ...
... The R4Mplus offers global companies a ... meet RFID compliance initiatives. With die-cast ... variety of connectivity options, and complex ... a super value. Plus, the fully ...
... combines enhanced memory, processing capacity, ... reliable all-metal construction. Proven platform ... print speed make it the ... value reliability, productivity, consistent print ...
... companies a cost-effective and dependable performer ... With die-cast metal construction, centralized printer/encoder ... and complex multi-language font support, the ... the fully integrated RFID reader/encoder supports ...
Medicine Products: